StockData
Sangamo Therapeutics, Inc logo

Sangamo Therapeutics, Inc (SGMOQ) stock

SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026Market cap $39.43MP/E –Yield –

Sangamo Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Sangamo Therapeutics's enterprise value was $5.03M on Oct 19, 2026, against $96.92M a year earlier. Over the last 5 years it ranged from -$82.14M to $766.31M, with a median of $96.92M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Oct 19, 2026$5.03M-93.2%
2025Dec 31, 2025$74.52M-53.1%
2024Dec 31, 2024$158.75M–
2023Dec 29, 2023-$39.56M-125.4%
2022Dec 30, 2022$156.00M-76.1%
2021Dec 31, 2021$652.94M-51.6%
2020Dec 31, 2020$1.35B+143.1%
2019Dec 31, 2019$554.85M-21.9%
2018Dec 31, 2018$710.55M-47.3%
2017Dec 29, 2017$1.35B+620.0%
2016Dec 30, 2016$187.41M-69.0%
2015Dec 31, 2015$605.20M-41.1%
2014Dec 31, 2014$1.03B+40.3%
2013Dec 31, 2013$732.91M+182.1%
2012Dec 31, 2012$259.81M+302.4%
2011Dec 30, 2011$64.57M–

More Sangamo Therapeutics figures

See a number that looks wrong?